NightingaleFor Investors
Investor brief · September 2026Live at Emory University

Clinical trial data, cleaned at the source. Live, audited and contracted in six months.

Nightingale checks and cleans trial data where it is created, then delivers it to the sponsor's database with an audit trail on every value.

$340Kcontracted
37trials in pipeline
6 mosince founding
<$70Ktotal burn to date
GxPaudit complete

Nightingale is the operating brand of Curanostics Inc., a Delaware corporation · collected = cash received · contracted = signed agreements · pipeline = identified, not yet signed · External figures are sourced in §14 or marked as estimates.

00 · Investment summary

Summary

New to clinical trials? Sections i and ii explain how a trial runs and where the money is lost, in plain English, before any of the numbers below.

1
Live, audited, contracted

Live at Emory with a completed GxP audit. $340K in signed contracts and 37 pipeline trials in six months, on under $70K of total burn.

2
Regulatory timing

ICH E6(R3) is in force and the FDA launched Real-Time Clinical Trials in April 2026. The manual data layer has to change.

3
Large market, clear entry

$20B+ a year for the product we sell today (~20,000 trials a year at roughly $1M of data work each), with adjacent products reaching far larger markets.

4
Software margins, disciplined burn

80-85% gross margin at steady state. Break-even at about 11 trials a year (~$1.25M annual fixed cost at full team).

5
Defensible position

Works with any EDC, sells through exclusive CRO partners, and builds a cross-sponsor dataset.

i · Trials 101

What a clinical trial is, and how one runs.

Written for readers who have not worked in clinical research. Every term used later in this brief is defined here, and again in the glossary in the appendix.

What it is

A controlled experiment that tests whether a drug or device is safe and whether it works. Nothing reaches patients without one. A large trial takes 3-6 years and costs tens of millions of dollars.

Who runs it

The company that owns the drug is the sponsor. It usually hires a CRO (contract research organization) to run the operational work, and the trial itself happens at sites: hospitals and clinics, 50-150 of them on a large study.

Why timing is the whole game

A trial's value is not the data. It is the date the data is trusted, because that is when the sponsor can file with the regulator and the product can start earning.

The six stages of a trial

Stage 1Design
  • The protocol is written: the study's rulebook, saying who can enroll, what is measured, when, and in what units
  • Separate documents give their own instructions: lab manual, pharmacy manual, consent form, questionnaires, output specification
Stage 2Site setup
  • Each hospital is trained and activated
  • Every site has its own record system, its own labs and its own way of working, so 60 sites means 60 different setups
Stage 3Enrollment
  • Sites recruit participants and take consent
  • Usually the slowest stage, and the one sponsors most want to start earlier
Stage 4Data collection
  • Blood tests, scans, vital signs, questionnaires and wearable readings are taken at each visit
  • A coordinator then re-types those values by hand into the sponsor's trial database, the EDC (electronic data capture system, sold by Medidata, Veeva and Oracle)
Stage 5Review and queries
  • Monitors check the database for values that look wrong
  • Each question raised is a query: a formal request back to the site to check or correct one value. A large study produces roughly 97,000 of them
Stage 6Close and submit
  • Remaining queries are cleared and the database is frozen: database lock
  • The sponsor files with the FDA or the EMA and, if approved, can sell the product
The patternSophisticated science, manual plumbing
  • The measuring is advanced; moving the numbers between systems is done by people
  • The gap between a measurement being taken and it being usable is where the money goes
Who gets paidNobody owns the gap
  • The EDC vendor sells a database and is not responsible for what happens before data arrives
  • The CRO sells people, so more manual work is more revenue
  • The site is measured on enrollment, not on data quality

Terms in bold are defined again in the glossary in the appendix.

ii · How the data moves today

The official path is tidy. Every arrow is a person.

THE PATH A VALUE TAKESWHAT EACH HANDOVER COSTS1Trial sitesHospitals, clinics, labs,wearables, apps and paper.Every site has its ownsystems and its own setup.2Data collectionA coordinator reads eachvalue and types it into thesponsor's trial database,the EDC, by hand.3Review and queriesMonitors and data managerscheck for values thatcontradict the protocol andsend questions back.4Sponsor and CROoversightDashboards, reports andstatus meetings track whatis still open, weeks afterthe visit happened.5Clean, analysis-readydataThe last questions close,cleanup finishes and thedatabase is frozen so theanalysis can begin.6CompletionThe package goes to theregulator. If approved, thetreatment can be sold andreach patients.8.1 daysfrom visit to database8.23% typed wrong~97,000 queriesper Phase III study58% change nothing~36 daysfrom the last patientvisit to lock$555.7K a day$55.7K direct cost +~$500K forgone sales9.6 days per queryeach question emailed, answered, checked and closed by hand16.4 days when the data sits outside the database
Stages of the trial in the boxes. What each handover costs, in red between them. Sources for every figure are in the table below.

Add the gaps up and you have the problem. The stages are fine. The time, the effort and the money sit in the handovers between them: about 8 days to get a value in, tens of thousands of questions that mostly change nothing, and 36 days on average from the last patient visit to a locked database, at $555.7K for every day it runs late: $55.7K of direct cost plus ~$500K of forgone sales. And the delay is not only financial: those are days a treatment that works is not yet available to the patients waiting for it.

The same handovers, with the sources

HandoverWhat actually happensWhat it costs
Site to databaseA person reads a value off a hospital screen or a lab report and types it into a different system8.1 days to arrive 3
8.23% typed wrong 5
Database to reviewMonitors look for values that contradict the protocol~97,000 queries
58% change nothing 6
Review back to siteEach query is emailed, answered, checked and closed by hand9.6 days each
16.4 if held elsewhere
Last visit to lockThe backlog of unresolved problems is worked through36 days on average 3
Every day lateThe trial keeps running and the product is not yet earning$555.7K per day 7
$55.7K direct + ~$500K forgone sales

And a quieter problem upstream. The protocol, the lab manual, the consent form and the output specification are written and approved separately, and nobody reconciles them against each other. The protocol says kilograms, the lab reports pounds. The protocol allows a visit window of three days, the schedule says seven. These conflicts cost nothing on the day they are written and surface in month eight as queries, deviations and data that cannot be used.

This is the layer Nightingale replaces: not the science, not the database, but the manual handling between the source and the sponsor.

01 · The problem

Trial data is still re-keyed and cleaned by hand.

SponsorProtocolWhat is measured, when, in what units
Sponsor / CROEDC buildAccepts values the protocol forbids
Each labLab manualsFive labs, five sets of units
Sponsor / IRBPharmacy, consent, questionnairesDrift through amendments
Each siteSource systems40 sites = 40 different setups
58%changed nothing
~97,000

queries per Phase III study. Most confirm correct data was correct. 6

Cost of one day of delay 7
$555.7K / day
$55,716 direct cost~$500,000 forgone sales
02 · Why now

Regulators now expect traceable, real-time trial data.

In April 2026 the FDA launched Real-Time Clinical Trials, with data sent to regulators continuously instead of at database lock.

3.6M
data points per Phase III protocol, 3× a decade ago 1
+34% / yr
growth in connected devices in trials 2
8.1 days
from patient visit to sponsor database 3
8.23%
error rate when records are re-keyed by hand 5
Dec 2023FDA digital health guidanceFirst system data lands in is the official source
Sep 2025ICH E6(R3) in forceProve where every value came from
Jan 2026FDA + EMA AI principlesAI needs data you can trace back
Apr 2026Real-Time Clinical TrialsContinuous data to the regulator
Sep 2026ARPA-H SURPASSFederal funding for real-time, adaptive trials
Jan 2027E6(R3) Annex 2Same rules for decentralized trials and RWE

Traceability is becoming table stakes. Meaning is the harder problem. Sponsors can already show a regulator where a number came from. What they cannot easily show is that the number was collected under the definition the analysis assumes, rather than against a superseded protocol version or a different population. That check belongs where the data is assembled, not in the document written at the end, which is the layer we sell.

A second wave of trials is forming outside the US

China is scaling drug development

Its 2026-2030 industrial plan targets 20% annual growth and a quarter of the world's first-in-class drugs originating there 21.

Those assets are licensed westward

Licensing of China-developed drugs grew 36% year over year, past $120B in total deal value 21. The buyers are US and European pharma.

The trials land back under FDA and EMA rules

A licensed-in asset still needs registrational trials that meet Part 11 and E6(R3), with every value traceable to its source, wherever it was collected.

Where we fit: more programs crossing borders means more trials that have to prove where each data point came from, across sites and systems a sponsor does not control. That is the layer we sell, and it is neutral to the country, the site and the trial database.

03 · The solution

One layer between every data source and the sponsor's database.

It stores nothing. It checks study documents before enrollment, then cleans and delivers data for the whole trial.

WHAT GOES INNIGHTINGALE · RUNS FOR THE WHOLE TRIALWHAT COMES OUT The study's rulebook Protocol · endpoints Lab & pharmacy manuals Consent · questionnaires Data-entry guide · output spec The regulators' rulebook FDA guidance · Part 11 EMA (EU) · ICH E6(R3) The data · each site's own Hospital records (EHR) Labs · imaging · pharmacy Wearables · devices · apps Telehealth visits Handwritten notes · paper Real-world evidence 1 · Check the rulebook Study documents vs each other vs FDA / EMA / ICH → every conflict flagged 2 · Inventory What already exists, incl. real-world evidence 3 · Find the gap Sponsor's required output vs what exists → what to collect 4 · Run the data · fixed rules map field → convert unit → check range → deliver Same input always gives the same output. No retyping. AI reads documents; fixed rules decide. 5 · Watch it daily Gap re-checked on live data. Advance notice if an endpoint is at risk. 6 · Prove every step Audit trail per data point: created, verified, or fixed & flagged. ↻ steps 4-6 repeat every day until the last data point 7 · Close and submit Endpoints met? If not, why, and what to enroll. Submission-ready package for the regulator. 8 · Every trial feeds the cross-trial data layer Consented, de-identified, identically structured. The basis for Layer 3. Sponsor's EDCMedidata · Veeva · Oracle · any Sponsor's output formatExactly as specified Audit recordEvery value, every step RegulatorReal-time feed · submission package Storage stays with the sponsor. Layer 3 · synthetic control arms · digital twins · cross-trial discovery · new treatments
Hover a stage to trace its inputs and outputs.
◉AI readsDocuments, notes, scans, photos
▣Rules decideFixed rules you can read. No AI in the pipeline.
✕ Not a database✕ Not a CRO✕ Not a tool for sites✕ Not a regulated device
04 · What it is worth

What it is worth on one Phase III trial.

A made-up study, with the assumptions stated. 2,000 patients, 120 sites, 14 data sources, 3 years, a trial budget of about $82M at the published median of ~$41,000 per patient. Nothing here is a customer result: a measured before-and-after case study is the next milestone as the contracted trials run.

Without Nightingale
With Nightingale
Sources to reconcile
14 sources · 120 site setupsfive lab manuals, by hand
14 sources · connected onceall manuals reconciled on day one
Visit → data in database
8.1 daysre-keyed by coordinators
Minutesautomated, no retyping
Queries over the trial
~150,00058% change nothing
~60,000queries from conflicting study documents never happen
Errors from re-keying
~250,000 values8.23% of ~3M hand-entered fields
~0 · source errors flaggedevery value carries its origin
Cleanup before database lock
90 daysmodelled for a trial this size; industry average 36
~10 daysdata was clean as it arrived
Data-management labor
$1.3Mten-person team, three years
$0.4M70% of manual work removed
Direct cost of the lock delay
$5.0M90 days at $55,716
$0.6M80 days recovered, $4.5M saved
Sales forgone, if approved
~$45M90 days at ~$500,000, counted separately
~$5M~$40M brought forward, shown separately
Audit trail at submission
Partialreconstructed after the fact
Completeevery value, every step, E6(R3)-ready
~$5.4M
direct savings (delay cost and data labor), 1.6x the contract
~$3.3M
Nightingale contract, 2.6% of budget
~$40M
sales brought forward if the drug is approved, counted separately

A hypothetical scenario, not measured performance. Published per-study figures scaled to 2,000 patients; the 90-day cleanup (against an industry average of 36 days 3) and the 60% query reduction are modelling assumptions. Direct cost and forgone sales are priced per day 7 and shown separately in this scenario. Depending on trial size, the model produces 63-80 days of earlier completion. The four numbers that land hardest on customer calls are enrollment start, query volume, earlier completion and the cost difference. These are the figures the contracted trials are being measured against; what is signed and live today is in the next section.

05 · Traction

Six months and under $70K of total burn.

Everything above this line is modelled, except the back-test below. Everything below it is signed, audited or live.

$340K
Signed contracts: Emory ($40K) and two device trials via Thinq CRO ($300K). $40K is being paid out now, so the company is already post-revenue.
37
Pipeline trials, identified but not yet signed
<$70K
Total burn since founding in Feb 2026
Validated

Back-tested on 718 completed neurology trials (181,302 participants). On 260 held-out trial arms, 82% of outcomes landed inside the 80% forecast range, against 51% for the standard method, with 1.7% false alarms.

Highlight

DIA invited the CEO to speak with a booth, and DIA's CEO offered a personal introduction to Pfizer. Nightingale is also a case study in USC's Regulatory Science curriculum.

Buyer access · meetings, reported as meetings

PfizerDirector
Eli LillyAssoc. director
OtsukaC-suite
RohtoC-suite
Mitsubishi TanabeDirector
MerckMeeting
RocheMeeting
Korean governmentMeeting
Harvard Innovation LabJoslin Diabetes CenterCambridge Innovation Center, JapanClearTrials partnerFDA advisory committee member on team
06 · Market

A $20B+ a year market for trial data, growing into much larger ones.

About 20,000 industry trials start each year 13. Running the whole data layer of one trial is worth roughly $1M, so the market for the product we sell today is $20B+ a year. Early contracts are smaller because they cover part of a trial; the same platform extends to adjacent products with far larger markets behind them.

$2T+ Layer 3 · medicines and devices $350B Layer 2 · health R&D $20B+ Layer 1 · trial data
Layer 1 · trial data infrastructure · the business today
$20B+a year, full scope

This is the market this brief is about. Every interventional trial has to get data out of hospital systems, labs and devices and into a study database a regulator will accept. That work is bought today, from CROs and data-management teams, on every study. We replace the manual part of it.

What one trial is worth at full scope: Phase III $1.2-1.4M, Phase II ~$550K, device ~$450K. Contracts start smaller, at the rulebook and gap analysis, and grow as the pipeline runs for the life of the study. The second trial at the same sponsor costs us far less to deliver, because the connections and the format library already exist.

The pool keeps growing: more than 35,000 new studies register each year, about 20,000 of them addressable 13. Layers 2 and 3 below are the same engine pointed at adjacent work. They are upside, not the plan.

Layer 2 · adjacent products, all health R&D
$30B+a year

About 15,000 prospective studies a year sit in this layer, the balance of the 35,000+ registered annually once the ~20,000 in-scope interventional trials are counted 13. They are the prospective studies that run after approval: Phase IV and post-marketing commitments, prospective real-world evidence studies, device post-market surveillance, and diagnostic and digital-health studies. They pull from the same sources under the same rules, and run for years rather than months. Behind them sits pharma R&D of about $300B a year, plus devices, diagnostics and digital health at about $50B 12.

Layer 3 · adjacent products, the data itself
$50Ba year

Once many trials have been run through the same checks, their data shares one structure. That structure is a scaffold: a frame with the shape of a real trial, which can be filled with modelled patients instead of recruited ones. Regulators already accept a limited version of this, called a modelled or synthetic control arm, where the comparison group is generated from prior trial data rather than by giving patients a placebo. Further out, the same scaffold supports simulating a candidate drug before it is tested. This layer is not a product today and is not in any forecast 11.

The trial pool this applies to

35,000+
new studies registered every year 13
~20,000
interventional trials a year in scope, our estimate 13
~28.5%
of interventional trials are industry-sponsored; the rest are academic, hospital or government 22
Every phase
Phase I to IV, plus device, diagnostic and software studies

In scope means interventional trials collecting from more than one electronic source and reporting into a study database. Registry-only and single-source observational studies are excluded. Industry-sponsored trials carry full pricing; academic and hospital studies are served at smaller scope, which is why the $20B+ figure is an upper bound rather than a forecast.

Longer term: the same data supports modeled control arms, which regulators already accept in steps (FDA 2023 guidance, an EMA-qualified digital-twin method 20).

07 · Business model

Sponsors pay per trial. CROs distribute. Margins look like software.

Sponsors hold the budget and pay per trial. CROs bring portfolios of them. We set the payment structure with each sponsor and break it across the trial rather than asking for it up front. Every engagement starts with the rulebook and gap analysis, and the aim is a sponsor who signs for the whole product, the rulebook and gap analysis plus the data pipeline, in which case the rulebook and gap analysis are free. Price a study in the calculator below.

Contract per trial$150Ktoday · signed device trials
Mature average~$1MPhase III $1.2-1.4M · Phase II ~$550K · device ~$450K
Gross margin80-85%steady state
Deployment4 → 2 wkfirst vs second trial
Break-even~11 trials / yrfixed cost ~$1.25M / yr at full team
Paid across milestones

Start of enrollment, midpoint, end. It matches the sponsor's own spend curve and shortens the procurement argument.

Lead with the rulebook, land the pipeline

The rulebook and gap analysis is the fast, low-risk way in, and we give it away when the sponsor commits to the full product. We trade margin at the entry point for a place in the study, which is where the pipeline earns for the life of the trial.

The value lens customers use

In the modelled Phase III, direct savings of about 1.6x the fee from fewer late days and less data-handling work. Earlier sales, if the drug is approved, are counted separately.

Go-to-market

ChannelCROsExclusive partners; $300K of $340K came this way
BuyerSponsorsHold the budget; after the first trial, reviews are skipped
BeneficiarySitesNever a customer; workload goes down

How sponsors buy · price a trial

1,650
3001,6503,000
6
3
1
150
Volume discount0%
TierSingle trial
Saved per trial$0
Portfolio saving$0

Discount grows with each doubling of trials committed, capped at 10%.

Nightingale · per trial
·

Share of trial budget·
Share of the ~10% technology budget·
Portfolio total (1 trial)·
What the sponsor gets back
·

Direct benefit over the trial

Days saved on the trial·
Manual data handling removed·
Delay avoided, direct cost (30 days)·
Earlier revenue if approved, not in total·
Return
·

in direct savings for every dollar spent on Nightingale

Estimated trial budget·
Technology budget (~10%)·
Net direct gain to the sponsor·

Budget from ~$41,000 per patient 10; savings from a data-management team scaled to enrollment 89 and delay days at $55,716 direct cost per day 7. Earlier revenue, at ~$500,000 per day, is counted in full only for studies that lead to market (15% at Phase I, 35% at Phase II) and is shown separately: it is not in the total or the return. Days saved is an output, not an input: 14 days of head start before the first patient, plus up to 49 days of cleanup slip avoided, 8 days per connected eSource.

08 · Competition & moat

Why incumbents cannot easily copy this.

1 · Neutrality

EDC vendors are not neutral to competing EDCs or to each site's own systems.

2 · Embedded & exclusive

Each trial adds connectors, and CRO partnerships are exclusive.

3 · A growing format library

Every trial adds lab and device formats that a single sponsor cannot rebuild.

4 · The data itself

Validated, source-linked data across sponsors.

EDC vendorsMedidata, Veeva, OracleNot neutral; one path into one product
Record connectorsIgniteDataOne source type; no rulebook check
AI data cleaningSaama, eClinical SolutionsDownstream: faster fixing, not prevention
Study-build toolsFaro Health, Certara FormedixUpstream only; nothing moves data after
Decentralized trialsMedable, THREADCreate sources; do not reconcile them
Twins & modeled controlsUnlearnLicensed data, unvalidated at source
Real-world dataFlatiron, Tempus, Komodo, TruvetaNot trial-grade, not at the source
NightingaleAt the source, every source, every sponsorRulebook check → pipeline → monitoring → audit trail → cross-sponsor data
09 · Growth plan

Target: 36+ live trials by August 2027.

Sep 2026 · todayLive at Emory$340K contracted · 37-trial pipeline · GxP audit complete
NextContracted device trials startSecond-sponsor proof, measured identically to Emory · SOC 2 Type II in progress
Feb 2027 · target12-18 trials livePipeline conversion, plus second and third trials at live sponsors
Aug 2027 · target36+ trials liveDriven by pipeline conversion and two further exclusive CRO partners
Trials live, from Feb 2026
1Feb 2026
3+6 mo
12-18+12 mo
36++18 mo
Accounts needed for $100M a year
Top-10 sponsor, embedded
1
Top-10, partial
3
Mid-cap biotech
17

Top-10 embedded: 60 trials/yr at $2M = $120M.

Targets, not commitments. The ramp requires pipeline conversion above 35%.

10 · Team

Three full-time founders, each with a prior exit.

YVYash VagalCEOFormer startup advisor and VC; 2x healthtech founder. Georgia Tech. Sponsor and CRO relationships.
SBShoale BadrCTOExited healthtech founder. Georgia Tech. Built the model, pipeline and audit engine.
GMGokul MohantyCSOExited founder; advisor and board member to 16 companies. Research, positioning, investors.

First hire: a commercial lead with clinical-trial domain fluency. Selling is learnable; knowing how a sponsor actually buys, and how a study runs, is the scarce part in this market.

Advisors: a sitting FDA advisory committee member, USC Regulatory Science faculty, senior sponsor clinical-ops leaders, and two founders who exited a trials company to a major Japanese CRO. All in a personal capacity; no institution endorses Nightingale.

11 · The round

Raising $2.5M on a SAFE for 24 months of runway.

Raise
$2.5M
Instrument
SAFE
Runway
24 months
Break-even
~11 trials / yr
Next round
Seed, on revenue
Use of funds, 24 months
Team and operations: $1M (40%)Engineering and product: $675K (27%)Sales and partnerships: $550K (22%)Infrastructure and compute: $125K (5%)Compliance and security: $100K (4%)Contingency: $50K (2%)$2.5M24 months
Team and operationsCFO hire, founder salaries, legal, insurance$1M40%
Engineering and productEngineers #1 and #2, pipeline scale-out$675K27%
Sales and partnershipsFirst account executive, CRO partner program, conferences$550K22%
Infrastructure and computeHosting, environments, data processing$125K5%
Compliance and securitySOC 2 Type II, GxP, Part 11 validation, pen testing$100K4%
ContingencyPayment-terms and hiring buffer$50K2%

Allocation follows our financial model, scaled to $2.5M with a 2% contingency. Team grows from 4 to 7 full-time. Fixed cost and break-even are estimates at full team; full model available in the data room.

Return potential · comparable revenue multiples 18

Snowflakeat IPO, 2020
>100×
Palantir2025
~80×
Cloudflare2025
~35×
Databricksprivate, 2025
~27×
Nightingaleunderwriting band
25-50×

$100M at 25-50× is a $2.5-5B outcome. The billion-dollar line is crossed at $20-40M of revenue.

Comparables are illustrative, not a forecast. A seed valuation prices the outcome; see §12 for what could go wrong.

12 · Risks

Key risks and mitigations.

RiskWhy it is realMitigationSeverity
Second-sponsor reproduction

Why

Emory's metrics are n=1.

Mitigation

The two contracted device trials are the test, measured identically. Each trial makes us integral to that sponsor's build.

High
Pipeline conversion

Why

The ramp needs 35-50% of 37 trials; no conversion history yet.

Mitigation

Rulebook-check entry lowers the first yes; CRO partners convert portfolios. First metric at every board meeting.

High
CRO concentration

Why

88% of contracted value came through one partner.

Mitigation

Exclusivity means a partner's full trial flow comes with it; two more partners targeted through DIA; direct sponsor conversations in parallel.

High
Start and payment timing

Why

$340K contracted, $40K being paid out. The two device trials begin when their sponsors close financing; pharma pays on 60-90 day terms.

Mitigation

Buffer carried in the raise; earlier milestones on new contracts; the raise does not depend on either trial's start date.

Medium
Breach or audit finding

Why

We touch patient data.

Mitigation

GxP complete, SOC 2 in progress, cyber and E&O insurance; storage stays with the sponsor, limiting what any incident can reach.

Medium
Key person

Why

Relationships in the CEO; architecture in the CTO.

Mitigation

Standard vesting; the model and pipeline are documented as validated systems, which the compliance posture requires anyway.

Medium
What we do not claim
No FDA approval claimed or neededReal-Time Clinical Trials is a demo programAdvisor ≠ FDA endorsementEmory results are n=1No conversation is a contract§05 trial is illustrative$2T is the market shaped, not invoiced
13 · Investor FAQ

Investor FAQ

Tap a question for the full answer.
In shortThe layer has to be neutral across EDCs and connect to every site. Incumbents are not built for either.
In shortYes. We are live on real patient data and have passed a GxP vendor audit.
In shortEach sponsor is a repeat buyer across many trials, and CRO partners add trials without new sales cycles.
In short$20B+ a year for trial data infrastructure, with adjacent markets beyond trials.
In shortData rights are in every contract, and the engineering to use the data stays with us.
14 · Get in touch

Talk to the founder.

Pick a time for an intro call, or reach out directly.

Yash Vagal
Co-Founder and CEO, Nightingale

We will walk through the product, traction, and the round, and answer anything this brief leaves open.

Intro callVideo callTerms on request
Book an intro call

What happens next

1Intro call

Product, traction and the $2.5M SAFE round.

2Follow-up

Terms and any materials you request.

3Reference call

A call with our flagship deployment, on request.

15 · Appendix · sources & glossary
Show all 20 sources
  1. Tufts Center for the Study of Drug Development (2021): Phase III protocols average 3.6 million data points, three times the volume of ten years earlier.
  2. Marra C. et al. (2020), npj Digital Medicine: connected digital products in trials grew ~34% per year, 2000-2017.
  3. Tufts CSDD and Veeva Systems, eClinical Landscape Study (2017): 257 organizations; median 8.1 days from patient visit to EDC entry; 36 days on average from last patient last visit to database lock.
  4. Advarra, Study Activation Survey 2023: N>500 sites; ~69% use six or more sponsor systems.
  5. Garza M. et al. (2026): manual transcription error rate 8.23%; integrated capture showed no detected transcription errors.
  6. Stokman P. et al. (2021), Journal of the Society for Clinical Data Management 1(1), DOI 10.47912/jscdm.20: 20 Phase III studies, 1,939,606 queries; ~96,980 per study; 42% resulted in a data change.
  7. Smith Z., DiMasi J., Getz K. (2024), Therapeutic Innovation & Regulatory Science 58(5):855-862: direct cost of trial delay $55,716/day; opportunity cost on the order of $500,000/day.
  8. Salary.com, US Clinical Data Manager compensation, September 2026: average $144,625, ~$70/hour.
  9. Vendor-sponsored industry survey, n=88: ~12 hours/week per data manager per study on query and reconciliation work. Indicative.
  10. Moore T. et al. (2018), JAMA Internal Medicine: median cost per patient in pivotal trials ~$41,117. Per-source and fixed-cost components are estimates.
  11. IQVIA Institute, Global Use of Medicines: global medicine spending ~$1.6T. Medical device market ~$600B (industry estimate). WHO: global health spending ~$10T.
  12. Evaluate Pharma / IFPMA: pharmaceutical R&D ~$300B per year; medtech and digital-health R&D ~$50B (estimate). IQVIA Technologies, Veeva and Medidata combined revenue ~$10B.
  13. ClinicalTrials.gov: more than 35,000 new studies registered per year. The ~20,000 addressable interventional figure is an estimate.
  14. ClinicalTrials.gov sponsor records: Pfizer ~423 tracked / 251 active; Eli Lilly ~333. Order-of-magnitude proxy.
  15. ICH E6(R3): §3.16.1(c), §3.16.2(c), §2.12. Step 4 6 Jan 2025; EU 23 Jul 2025; FDA 9 Sep 2025; Annex 2 adopted 3 Jun 2026, effective 15 Jan 2027.
  16. FDA Digital Health Technologies guidance (Dec 2023); FDA Part 11 Q&A (Oct 2024); FDA and EMA AI principles (Jan 2026); FDA Real-Time Clinical Trials (28 Apr 2026); HHS and ARPA-H SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), solicitation ARPA-H-SOL-26-164 (30 Sep 2026).
  17. Disclosed transactions: Change Healthcare/Optum $13B; Datavant/Ciox ~$7B; Komodo Health $3.3B; Flatiron Health/Roche $1.9B; Truveta >$1B; Tempus AI market capitalization ~$10.6B.
  18. Public revenue multiples: Snowflake at IPO >100× trailing; Palantir ~80× (2025); Cloudflare ~35× (2025); Databricks ~27× (private, 2025).
  19. Private comparables: a September 2026 software seed round at $7M on $100M post-money with ~$500K lifetime revenue; a clinical-trial software company that raised under $400K in total and sold for roughly half a billion dollars. Details available on request.
  20. FDA, Considerations for the Design and Conduct of Externally Controlled Trials, draft guidance, February 2023. EMA, qualification opinion on prognostic covariate adjustment using digital twins (PROCOVA), September 2022.
  21. BioSpace, "China plans to transform biotech sector into $522B powerhouse by 2030," September 18, 2026, reporting China's Ministry of Industry and Information Technology 2026-2030 plan: 20% annual industry growth, 25% of global first-in-class drugs originating in China, and licensing of China-developed drugs up 36% year over year, past $120B in total value.
  22. Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019, JAMA Network Open (2020): of 245,999 interventional studies, 70,329 (28.5%) were industry-sponsored.
Plain-language glossary
Plain-language glossary · the terms this document uses
EDCElectronic Data Capture: the sponsor's trial database, the official record. Medidata, Veeva and Oracle sell them.
eSourceAny electronic system at a hospital or clinic that holds trial data: the EHR, a lab system, a wearable, a patient app.
EHRElectronic Health Record: the hospital's patient chart.
CROContract Research Organization: a company sponsors hire to run trials.
QueryA question raised when a data value looks wrong. Each one is a person-hour of chasing.
Database lockThe moment a trial's data is frozen for analysis. Every day of cleanup before it is a day of delay.
Real-world evidence (RWE)Health data from outside the trial (records, claims, devices) that the FDA encourages sponsors to use.
Audit trail / chain of custodyThe recorded history of where a data point came from and every change made to it. Regulators require it.
Synthetic control armA comparison group modeled by computer from prior trial data, instead of recruiting patients to take a placebo.
Digital twinA computer replica of one patient, used to predict how that patient would respond to a dose or a device.
ICH E6(R3)The international standard for how trials must be run, in force in the US, EU, Japan, Korea and Canada.
eCRFElectronic Case Report Form: the screens in the EDC where trial data is entered.